Clinical Trial

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Study acronym: MAGENTA
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. After Cohort A, Cohort B will evaluate mezigdomide + dexamethasone followed by step-up dosing of talquetamab (mezigdomide + talquetamab,+ dexamethasone).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-16; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2026-04-07
Trial Details
NCT Number NCT07032714
Lead Sponsor Massachusetts General Hospital
Collaborators: Celgene Corporation, Janssen Research and Development LLC
Conditions Relapsed Refractory Multiple Myeloma (RRMM)
Enrollment 25 participants
Start Date 2025-12-19
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13